Atezolizumab for High PD-L1 Stage IV Non-Small Cell Lung Cancer

This study focuses on evaluating the effectiveness and safety of a drug called atezolizumab for patients with an advanced form of lung cancer known as stage IV non-small cell lung cancer (NSCLC). The patients participating in this trial have not previously received chemotherapy and have high levels of a specific protein called PD-L1, which is found on the surface of some cancer cells. This study is important because it aims to offer a new treatment option for patients who have limited alternatives, especially those whose cancer cells have a high PD-L1 expression but do not have certain genetic mutations, making them more challenging to treat effectively. Participants in the study will receive atezolizumab, a medicine designed to help the immune system recognize and attack cancer cells, through an intravenous injection. The main goal of the study is to determine how long patients live after starting treatment with atezolizumab, which is referred to as overall survival. By closely monitoring these patients, researchers hope to understand better the potential benefits and any risks of this treatment in extending life expectancy for those with this specific type of lung cancer.